Aclaris Therapeutics, Inc. ACRS
5.15
(0.23)
(4.28%)
as of 25 Sep
- Market cap
- $589.0M
- P/E
- 0.0×
Follow ACRS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(113.23%) | (50.20%) | (48.42%) | (59.10%) | |
| (79.17%) | (34.10%) | (35.11%) | (41.07%) | ||
ROIC |
(396.16%) | (387.11%) | (131.57%) | (163.35%) | |
Return on Tangible Assets |
(186.98%) | (94.87%) | (83.32%) | (107.91%) | |
Average Days of Receivables |
108.52 | 259.55 | 210.00 | 275.74 | |
Free Cash Flow per Share |
(0.35) | (0.39) | (0.41) | (0.44) | |
Free Cash Flow |
(43.01) | (47.22) | (52.29) | (62.18) | |
Capital Expenditures |
(0.09) | (0.11) | (0.08) | (0.12) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(19.87%) | (24.31%) | (20.96%) | (28.71%) | |
Accounts Receivable Turnover |
6.27 | 0.87 | 3.30 | 2.57 | |
Accounts Payable Turnover |
1.79 | 0.82 | 0.72 | 0.59 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
221.83 | 659.35 | 711.60 | 791.08 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
286.43% | 672.69% | 677.88% | 770.59% | |
Selling, General and Administrative Expense of Revenue |
135.63% | 280.76% | 269.82% | 282.74% | |
Share Based Compensation of Revenue |
78.25% | 158.24% | 143.98% | 141.82% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.30 | 0.73 | 0.75 | 0.82 | |
Depreciation/Fixed assets |
0.61 | 0.60 | 0.57 | 0.63 | |
Capex/Depreciation |
(0.18) | (0.24) | (0.19) | (0.28) | |
Revenue per Share |
0.13 | 0.06 | 0.07 | 0.06 | |
Operating CF per Share |
(0.35) | (0.38) | (0.41) | (0.43) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Net Profit Margin |
(900.07%) | (829.58%) | (832.58%) | (921.50%) |
Columns are period end dates